Abstract:Neurodevelopmental and neurodegenerative diseases (NDDs) with severe neurological/psychiatric symptoms, such as cerebrovascular pathology in AD, CAA, and chronic stroke, have brought greater attention with their incidence and prevalence having markedly increased over the past few years. Causes of the significant neuropathologies, especially those observed in neurological diseases in the CNS, are commonly believed to involve multiple factors such as an age, a total environment, genetics, and an immunity contributing to their progression, neuronal, and vascular injuries. We primarily focused on the studies of glial involvement/dysfunction in part with the blood-brain barrier (BBB) and the neurovascular unit (NVU) changes, and the vascular mechanisms, which have been both suggested as critical roles in chronic stroke and many other NDDs. It has been noted that glial cells including astrocytes (which outnumber other cell types in the CNS) essentially contribute more to the BBB integrity, extracellular homeostasis, neurotransmitter release, regulation of neurogenic niches in response to neuroinflammatory stimulus, and synaptic plasticity. In a recent study for NDDs utilizing cellular and molecular biology and genetic and pharmacological tools, the role of reactive astrocytes (RACs) and gliosis was demonstrated, able to trigger pathophysiological/psychopathological detrimental changes during the disease progression. We speculate, in particular, the BBB, the NVU, and changes of the astrocytes (potentially different populations from the RACs) not only interfere with neuronal development and synaptogenesis, but also generate oxidative damages, contribute to beta-amyloid clearances and disrupted vasculature, as well as lead to neuroinflammatory disorders. During the past several decades, stem cell therapy has been investigated with a research focus to target related neuro-/vascular pathologies (cell replacement and repair) and neurological/psychiatric symptoms (paracrine protection and homeostasis). Evidence shows that transplantation of neurogenic or vasculogenic cells could be achieved to pursue differentiation and maturation within the diseased brains as expected. It would be hoped that, via regulating functions of astrocytes, astrocytic involvement, and modulation of the BBB, the NVU and astrocytes should be among major targets for therapeutics against NDDs pathogenesis by drug and cell-based therapies. The non-invasive strategies in combination with stem cell transplantation such as the well-tested intranasal deliveries for drug and stem cells by our and many other groups show great translational potentials in NDDs. Neuroimaging and clinically relevant analyzing tools need to be evaluated in various NDDs brains.

The 2023 Yearbook of Neurorestoratology

The 2022 Yearbook of Neurorestoratology

The 2021 yearbook of Neurorestoratology

The 2020 Yearbook of Neurorestoratology

2016 Yearbook of Neurorestoratology

The 2019 Yearbook of Neurorestoratology

2017 Yearbook of Neurorestoratology

Neurorestoratology: New Advances in Clinical Therapy

Stem Cells for the Treatment of Neurodegenerative Diseases

Beijing Declaration of International Association of Neurorestoratology (2023 Xi'an Version)

Neurorestoratologic Strategies and Mechanisms in the Nervous System

Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017)

Join us on an amazing journey towards next‐generation treatments for CNS disorders: Launch of Neuroprotection, a new high‐quality journal in translational neuroscience

Automatic Theranostics for Long-Term Neurorehabilitation after Stroke

Neuro-regeneration or Repair: Cell Therapy of Neurological Disorders as A Way Forward

Recent Insights into the Neurobiology of Alzheimer's Disease and Advanced Treatment Strategies

New Mechanistic Insights, Novel Treatment Paradigms, and Clinical Progress in Cerebrovascular Diseases

Top ten discoveries of the year: Neurodegeneration

Glial Cell-Based Vascular Mechanisms and Transplantation Therapies in Brain Vessel and Neurodegenerative Diseases